Momenta Pharmaceuticals CEO Hosts Investor Conference Call To Discuss Follow-On Biologics Collaboration With Baxter (Transcript)

Momenta Pharmaceuticals, Inc. (MNTA)

Baxter International Inc. Collaboration Conference Call

December 23, 2011 10:00 am ET


Beverly Holley – Director, Investor Relations

Craig A. Wheeler – President and Chief Executive Officer

Richard P. Shea – Chief Financial Officer

Ganesh Venkataraman Ph.D. – Senior Vice President, Chief Scientific Officer


Ritu Baral – Canaccord Genuity

Sapna Srivastava – Goldman Sachs

Ami Fadia – UBS

Eric Schmidt – Cowen & Company

Bret Holley – Oppenheimer & Co.

Sumant Kulkarni – Bank of America/Merrill Lynch

Joseph P. Schwartz – Leerink Swann & Company

Duane Nash – Wedbush Securities

Alan Sonnenfeld – Bernstein

Avik Roy – Monness, Crespi, Hardt

Rajeev Jashnani – UBS Investment Bank

Frank Rango – Purchase Capital Management



Good day, ladies and gentlemen, and welcome to the Momenta Biosimilars Update. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to introduce your host for today's conference, Beverly Holley, Director of Investor Relations.

Beverly Holley

Thank you, and good morning. I want to welcome all of you to Momenta's conference call to discuss our recently-announced follow-on biologics collaboration with Baxter. With me on the call today with prepared remarks is Craig Wheeler, our President and Chief Executive Officer. Also present are Rick Shea, our CFO, and Ganesh Venkataraman, our Chief Scientific Officer. Following our remarks, we will open the call to questions.

If you liked this article you might like

Teva Must Clear Three Big Hurdles to Reclaim Its Perch

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Analysts' Actions -- Discovery, First Solar, Momenta, VF Corp. and More

Sarepta Leads Biotech Movers on Voucher Deal News